Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 10

PMID 35267584

Authors

Adrian Minson

Constantine Tam

Michael Dickinson

John F Seymour

Affiliations

Soon will be listed here.

Abstract

Targeted therapies continue to change the landscape of lymphoma treatment, resulting in improved therapy options and patient outcomes. Numerous agents are now approved for use in the indolent lymphomas and many others under development demonstrate significant promise. In this article, we review the landscape of targeted agents that apply to the indolent lymphomas, predominantly follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia and marginal zone lymphoma. The review covers small molecule inhibitors, immunomodulators and targeted immunotherapies, as well as presenting emerging and promising combination therapies.

Citing Articles

Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.

Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J Front Immunol. 2022; 13:943354.

PMID: 35979372 PMC: 9376239. DOI: 10.3389/fimmu.2022.943354.

References

Stephens D, Byrd J . Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021; 138(13):1099-1109. PMC: 8570054. DOI: 10.1182/blood.2020006783. View

Phillips D, Xiao Y, Lam L, Litvinovich E, Roberts-Rapp L, Souers A . Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015; 5:e368. PMC: 4670945. DOI: 10.1038/bcj.2015.88. View

Bachiller M, Battram A, Perez-Amill L, Martin-Antonio B . Natural Killer Cells in Immunotherapy: Are We Nearly There?. Cancers (Basel). 2020; 12(11). PMC: 7694052. DOI: 10.3390/cancers12113139. View

Woyach J, Johnson A . Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015; 126(4):471-7. PMC: 4513250. DOI: 10.1182/blood-2015-03-585075. View

Fouquet G, Guidez S, Petillon M, Louni C, Ohyba B, Dib M . Lenalidomide is safe and active in Waldenström macroglobulinemia. Am J Hematol. 2015; 90(11):1055-9. DOI: 10.1002/ajh.24175. View

Yu S, Yi M, Qin S, Wu K . Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1):125. PMC: 6701025. DOI: 10.1186/s12943-019-1057-4. View

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, OConnor O . Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2020; 137(19):2634-2645. PMC: 8138546. DOI: 10.1182/blood.2020007512. View

Parker K, Migliorini D, Perkey E, Yost K, Bhaduri A, Bagga P . Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020; 183(1):126-142.e17. PMC: 7640763. DOI: 10.1016/j.cell.2020.08.022. View

10.

Sehn L, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K . Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016; 17(8):1081-1093. DOI: 10.1016/S1470-2045(16)30097-3. View

11.

Li B, Wan Q, Li Z, Chng W . Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. Cancers (Basel). 2021; 13(20). PMC: 8533975. DOI: 10.3390/cancers13205147. View

12.

Selim A, Minson A, Blombery P, Dickinson M, Harrison S, Anderson M . CAR-T cell therapy: practical guide to routine laboratory monitoring. Pathology. 2021; 53(3):408-415. DOI: 10.1016/j.pathol.2021.02.002. View

13.

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

14.

Ogura M, Tobinai K, Hatake K, Davies A, Crump M, Ananthakrishnan R . Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2016; 22(19):4807-4816. DOI: 10.1158/1078-0432.CCR-15-2488. View

15.

Abedin S, Boddy C, Munshi H . BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther. 2016; 9:5943-5953. PMC: 5047722. DOI: 10.2147/OTT.S100515. View

16.

Burger J, Wiestner A . Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018; 18(3):148-167. DOI: 10.1038/nrc.2017.121. View

17.

Hunter Z, Yang G, Xu L, Liu X, Castillo J, Treon S . Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017; 35(9):994-1001. DOI: 10.1200/JCO.2016.71.0814. View

18.

Curigliano G, Shah R . Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Saf. 2019; 42(2):247-262. DOI: 10.1007/s40264-018-0778-4. View

19.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

20.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View